查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018796

多發性骨髓瘤治療市場：依藥物類別、給藥途徑、產品類型及通路分類－2026-2032年全球市場預測

Multiple Myeloma Therapeutics Market by Drug Class, Mode Of Administration, Product Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年多發性骨髓瘤治療市場價值為 246 億美元，預計到 2026 年將成長至 263.8 億美元，複合年成長率為 7.36%，到 ​​2032 年將達到 404.8 億美元。

主要市場統計數據
基準年 2025 246億美元
預計年份：2026年 263.8億美元
預測年份 2032 404.8億美元
複合年成長率 (%) 7.36%

全面概述科學突破、不斷發展的交付模式和支付方趨勢如何匯聚，從而重新定義多發性骨髓瘤的治療路徑。

多發性骨髓瘤的治療處於科學創新、不斷發展的臨床實踐和複雜的商業性趨勢交匯的關鍵位置。細胞療法、標靶抗體、小分子藥物和給藥方法的進步正在重塑治療路徑，並重新定義療效、耐受性和長期疾病控制的預期。這些科學進步與治療方法的生產、報銷和交付方式的結構性變革同步發生，這使得相關人員更需要整合臨床、監管和營運方面的見解，並制定連貫的策略規劃。

近期科學突破、監管柔軟性和商業性創新如何重塑多發性骨髓瘤的治療途徑、進入模式和競爭挑戰。

多發性骨髓瘤的治療格局正在經歷一場變革性的轉變，這主要得益於科學突破、監管政策的調整以及商業模式的創新。細胞療法和新一代免疫療法正在拓展臨床可行的治療範圍，使治療模式從以細胞毒性為中心的序貫治療方案轉變為以深度緩解和延長無進展生存期為目標的持續性標靶治療。同時，基於生物標記的患者篩選和診斷準確性的提高，使得更合理的治療順序和聯合治療策略成為可能，這在增加臨床決策複雜性的同時，也推動了治療的個人化進程。

了解新關稅措施對下游供應鏈、定價和營運的影響，並掌握策略採購和製造選擇如何確保准入和商業性可行性。

2025年的關稅政策將為依賴跨國供應鏈和專業生產投入的治療藥物帶來新的營運和商業複雜性。進口關稅的引進和調整不僅會影響成品藥，還會影響活性藥物成分、生物製藥原料、一次性生物加工設備和低溫運輸物流服務等關鍵組件。因此，製造商和經銷商正在重新審視籌資策略、供應商合約和庫存政策，以在降低成本影響的同時，維持供應的連續性。

以細分市場主導的策略挑戰，旨在按藥物類別、給藥途徑、分銷管道和產品類型確定投資和商業化優先事項。

細分市場層面的洞察揭示了不同治療領域、給藥途徑、通路和產品類型所面臨的不同策略挑戰。按藥物類別分類，CAR-T療法呈現出獨特的開發和商業化模式，其特點是個人化生產、複雜的物流以及卓越中心（COE）交付模式。同時，組蛋白去乙醯化酶抑制劑作為重要的輔助性治療，在耐受性和聯合治療方面具有潛力。免疫調節劑在核心療法中繼續發揮核心作用，其生命週期管理正透過對新製劑和聯合治療的研究來實現。單株抗體和蛋白酶體抑制劑在治療序列中佔有至關重要的地位。特別是，Bortezomib、Carfilzomib和伊沙佐米等蛋白酶體抑制劑，各自具有不同的給藥方案、毒性考慮以及對臨床依從性的影響，從而影響臨床醫生的選擇。

美洲、歐洲、中東、非洲和亞太地區在實施狀況、基礎設施和償還制度方面的區域差異決定了准入途徑和戰略投資。

區域趨勢既影響多發性骨髓瘤新療法的引入速度，也影響其應用所需的運作前提。美洲地區創新治療方法的臨床應用率持續維持高位，且擁有完善的報銷體系，支持早期准入計畫。然而，該地區面臨嚴格的價格審查和以支付主導的估值框架，因此需要可靠的真實世界數據和基於療效的合約。在歐洲、中東和非洲（EMEA）地區，監管協調、區域採購機制以及醫療基礎設施的差異導致療法應用時間有差異。雖然西歐高所得市場的療法應用正在加速，但新興市場則優先考慮成本效益高且擴充性的解決方案。

競爭差異化越來越依賴可擴展的生產、證據產生、與支付方的合作以及加速患者獲得治療和增強商業性永續性的夥伴關係模式。

在多發性骨髓瘤治療領域，企業間的競爭格局日益受到核心藥物發現和臨床開發以外的能力的影響。組織敏捷性，例如能夠大規模生產複雜的生物製藥和細胞療法，在以療效為導向的醫保報銷談判中積累經驗，以及生成核准後真實世界數據（REW）的能力，如今已成為商業性成功的關鍵決定因素。專注於CAR-T和雙特異性抗體等平台技術的企業，正在投資建構端到端的價值鏈，涵蓋載體生產、低溫物流以及治療中心培訓等各個環節，旨在縮短患者用藥時間，並提高治療效果的一致性。

為製造商和相關人員提供可操作的策略，以確保供應彈性、基於證據的價值、適應性合約和以患者為中心的交付模式，從而加速部署。

產業領導者應優先考慮一系列切實可行的舉措，使科學研究潛力與病患和商業性成果相契合。首先，他們應積極投資於生產韌性和產能多元化，以降低供應鏈和關稅風險，包括認證替代供應商以及與契約製造製造商建立策略合作夥伴關係，以支持原料藥和特種生物製藥的生產。同時，應將真實世界資料（REW）的收集納入早期研發計劃，以支持監管申報、核准後的適應症擴展以及與支付方簽訂基於價值的契約，並確保資料收集的互通性和地域相關性。

採用嚴謹的混合方法研究途徑，結合二手文獻和針對性的相關人員訪談，來檢驗臨床、營運和商業性影響。

支持這些發現的研究結合了結構化的二手資料回顧、有針對性的專家訪談和主題整合，建構了一個平衡且以實踐為導向的觀點。二手資料分析包括對同行評審的臨床文獻、已發布的監管文件、臨床試驗註冊資訊和現有政策聲明的審查，梳理了近期核准、擴展適應症以及臨床實踐的變化。這些資訊來源使我們能夠揭示臨床和監管背景，並專注於治療機制、給藥方法和循證醫學要求，而無需依賴專有的市場規模估算或預測數據。

整合治療創新、營運績效和政策方面的趨勢，這些趨勢決定了多發性骨髓瘤患者獲得治療的速度和商業性成功。

總之，多發性骨髓瘤的治療格局呈現出快速創新以及隨之而來的複雜運作和商業需求的特徵。儘管科學進步拓寬了可行的治療策略範圍，但要大規模使患者獲益，需要在生產製造、物流、醫保合作和臨床應用等各個環節進行整合執行。價格和供應鏈趨勢帶來的新壓力，使得策略採購、近岸外包以及合約柔軟性成為維持藥物可及性和獲利能力的必要條件。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 多發性骨髓瘤治療市場：依藥物類別分類

  • CAR-T療法
  • 組蛋白去乙醯化酶抑制劑
  • 免疫調節藥物
  • 單株抗體
  • 蛋白酶體抑制劑
    • Bortezomib
    • Carfilzomib
    • 伊沙佐米

第9章：多發性骨髓瘤治療藥物市場（依給藥途徑分類）

  • 靜脈
  • 口服
  • 皮下

第10章 多發性骨髓瘤治療市場：依產品類型分類

  • 品牌商品
  • 非專利的

第11章 多發性骨髓瘤治療藥物市場：按分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 專科藥房

第12章 多發性骨髓瘤治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 多發性骨髓瘤治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 多發性骨髓瘤治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國多發性骨髓瘤治療市場

第16章：中國多發性骨髓瘤治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Adaptimmune Therapeutics plc
  • Amgen Inc.
  • Arcellx, Inc.
  • AstraZeneca plc
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • Cellectis SA
  • Daiichi Sankyo Company, Limited
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Ichnos Sciences
  • Ionis Pharmaceuticals, Inc.
  • iTeos Therapeutics
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Oncopeptides AB
  • Poseida Therapeutics, Inc.
  • Precision BioSciences, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-ED54C46E8354

The Multiple Myeloma Therapeutics Market was valued at USD 24.60 billion in 2025 and is projected to grow to USD 26.38 billion in 2026, with a CAGR of 7.36%, reaching USD 40.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.60 billion
Estimated Year [2026] USD 26.38 billion
Forecast Year [2032] USD 40.48 billion
CAGR (%) 7.36%

A comprehensive introductory perspective on how scientific breakthroughs, evolving delivery models, and payer dynamics are converging to redefine multiple myeloma care pathways

Multiple myeloma therapeutics sit at a pivotal intersection of scientific innovation, clinical practice evolution, and complex commercial dynamics. Advances in cellular therapies, targeted antibodies, small molecules, and administration modalities are reshaping treatment pathways and redefining expectations for efficacy, tolerability, and long-term disease control. These scientific advances are occurring alongside structural changes in how therapies are manufactured, reimbursed, and delivered to patients, intensifying the need for stakeholders to synthesize clinical, regulatory, and operational intelligence into coherent strategic plans.

Clinicians and health systems are navigating a wider array of therapeutic choices that span highly specialized cell therapies to more conventional proteasome inhibitors and immunomodulatory agents. Payers and policy-makers are responding to evidence on value and durability with evolving coverage frameworks and outcome-based contracting pilots. Meanwhile, manufacturers are contending with longer, more complex development pathways for advanced therapies that require parallel investments in manufacturing capacity, cold-chain logistics, and specialized workforce training. Together, these dynamics create both opportunity and risk: opportunities to deliver transformative patient benefits and capture differentiated commercial value, and risks tied to supply continuity, pricing pressures, and adoption barriers.

This introduction frames the subsequent sections, which examine the landscape shifts, tariff-related impacts on supply chains and costs, segmentation-driven insights across therapeutic classes and delivery channels, regional nuances, competitive behavior, actionable recommendations for industry leaders, and the methodology underpinning the intelligence gathered. The aim is to equip executive teams with a balanced, operationally grounded view that can inform near-term decisions and multi-year planning.

How recent scientific breakthroughs, regulatory flexibility, and commercial innovation are reshaping therapeutic pathways, access models, and competitive imperatives in multiple myeloma

The therapeutic landscape for multiple myeloma is undergoing transformative shifts driven by a confluence of scientific breakthroughs, regulatory adaptability, and commercial model innovation. Cellular therapies and next-generation immunotherapies are extending the boundaries of what is clinically feasible, prompting treatment paradigms to evolve from sequential, cytotoxic-focused regimens toward durable, targeted approaches that aim for deeper remissions and longer progression-free intervals. Parallel enhancements in biomarker-driven patient selection and diagnostic precision are enabling more rational sequencing and combination strategies, increasing the complexity of clinical decision-making while improving personalization of care.

Regulators are increasingly open to accelerated pathways and real-world evidence to inform approvals and label expansions, which shortens the time from proof-of-concept to broader clinical access but elevates the need for robust post-approval evidence generation and pharmacovigilance. Commercially, manufacturers are experimenting with innovative contracting arrangements, including outcomes-based agreements and multi-stakeholder risk-sharing constructs, to balance upfront pricing with long-term value delivery. Operationally, the rise of high-cost, capacity-constrained therapies has catalyzed collaborations between manufacturers, specialized providers, and logistics partners to manage manufacturing scale-up and equitable patient access.

Taken together, these shifts are altering competitive dynamics, with research-intensive players prioritizing cell therapy and bispecific platforms while established product classes such as proteasome inhibitors and immunomodulatory agents are being optimized through formulation changes and administration route innovations. Health systems are likewise adapting by investing in specialized centers of excellence and care pathways that can integrate new therapies while managing budgetary and infrastructure constraints. The net effect is a market environment defined by rapid innovation, increasing interdependence among stakeholders, and heightened execution risk tied to manufacturing, clinical adoption, and reimbursement alignment.

Understanding the downstream supply chain, pricing, and operational implications of new tariff measures and how strategic sourcing and manufacturing choices can preserve access and commercial viability

Tariff policies in 2025 introduced a new layer of operational and commercial complexity for therapeutics that rely on cross-border supply chains and specialized manufacturing inputs. The introduction or recalibration of import tariffs affects not only finished pharmaceutical products but also critical components such as active pharmaceutical ingredients, biologic raw materials, single-use bioprocessing equipment, and cold-chain logistics services. As a result, manufacturers and distributors are reassessing sourcing strategies, supplier contracts, and inventory policies to preserve continuity of supply while containing cost impacts.

The tariff environment has prompted a strategic pivot toward nearshoring and diversification of supplier networks, which can mitigate exposure to tariff volatility and geopolitical risk but may require capital investment and longer lead times to qualify new suppliers. In addition, increased import duties elevate the relative importance of domestic manufacturing capacity and contract development and manufacturing organization partnerships that can internalize some supply chain stages. For advanced therapies, where manufacturing yields, chain-of-identity controls, and cold-chain management are critical, tariff-induced changes to logistics and component costs can translate into higher operational complexity and potentially slower scaling of patient throughput.

From a pricing and reimbursement perspective, tariff-driven cost pressures necessitate proactive engagement with payers to demonstrate real-world value and to structure commercial arrangements that distribute risk across stakeholders. Manufacturers should consider scenario planning that quantifies potential cost impacts of tariffs on gross margins and identifies mitigations such as formulation changes that reduce dependency on tariff-exposed inputs, redesigned packaging, and logistics optimization. In summary, the 2025 tariff landscape underscores the need for strategic supply chain resilience planning, contract renegotiation, and targeted investments in local capacity to preserve access and protect commercial viability.

Segmentation-driven strategic imperatives across drug classes, administration routes, distribution channels, and product types that dictate investment and commercialization priorities

Segment-level insights reveal differentiated strategic imperatives across therapeutic classes, routes of administration, distribution pathways, and product types. Within drug classes, CAR-T therapy represents a distinct development and commercialization paradigm characterized by individualized manufacturing, complex logistics, and center-of-excellence delivery models, while Histone Deacetylase Inhibitors remain an important adjuvant class with opportunities around tolerability and combination regimens. Immunomodulatory drugs continue to play a central role in backbone therapy and are subject to lifecycle management through new formulations and combination studies. Monoclonal antibodies and proteasome inhibitors maintain an essential position in treatment sequencing; notably, proteasome inhibitors such as Bortezomib, Carfilzomib, and Ixazomib each present different administration profiles, toxicity considerations, and real-world adherence implications that influence clinician choice.

Administration mode segmentation highlights the growing preference for patient-centric delivery where feasible: intravenous delivery remains indispensable for many high-efficacy biologics and infusion-based regimens, oral therapies gain traction for convenience and chronic maintenance settings but pose adherence and drug-drug interaction management challenges, and subcutaneous formulations are increasingly developed to reduce clinic time and resource burden. Distribution channel dynamics show that hospital pharmacies continue to be critical for inpatient and infusion-delivered products, specialty pharmacies are central for managing complex therapies and coordinating patient support services, and retail pharmacies play a role in dispensing oral and maintenance medications with implications for patient adherence programs and co-pay assistance structures.

Finally, product type differentiation between branded and generic offerings drives distinct commercial strategies. Branded developers focus on innovation, evidence generation for label expansion, and premium pricing strategies underpinned by differentiated clinical data, whereas generic entrants and biosimilars emphasize cost competitiveness, formulary placement tactics, and rapid adoption in maintenance or post-patent-loss settings. Bridging these segmentation lenses enables a clearer understanding of where investment in manufacturing scale, patient support, and evidence generation will have the most meaningful impact on uptake, adherence, and long-term therapeutic positioning.

Regional adoption, infrastructure, and reimbursement contrasts that determine access pathways and strategic investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape both the pace of adoption and the operational prerequisites for delivering novel multiple myeloma therapies. The Americas continue to be characterized by high clinical adoption for innovative modalities and an advanced reimbursement ecosystem that supports early access programs; this region also faces pronounced pricing scrutiny and payer-driven value frameworks that require robust real-world evidence and outcomes-based contracting. In Europe, Middle East & Africa, regulatory harmonization, regional purchasing mechanisms, and variable healthcare infrastructure lead to heterogenous adoption timelines, with high-income markets in Western Europe accelerating uptake while emerging markets prioritize cost-effective and scalable solutions.

Asia-Pacific exhibits a complex mosaic of demand drivers: certain markets demonstrate rapid clinical uptake of novel biologics and cell therapies supported by targeted national investments in advanced therapy manufacturing capacity, while others emphasize local production and cost containment. Across regions, differences in patient demographics, comorbidity patterns, and healthcare delivery models influence ideal product profiles, such as a premium on oral convenience in ambulatory care-dominated systems or an emphasis on infusion efficiency in hospital-centric models. Supply chain resilience and local regulatory engagement strategies must be tailored to regional infrastructure realities to ensure patient access and sustainable commercialization.

Cross-region planning should therefore integrate localized evidence generation, adaptive pricing strategies, and investments in regional manufacturing or fill-finish capabilities where appropriate. Establishing partnerships with regional centers of excellence, payers, and patient advocacy organizations can accelerate acceptance and uptake, while transparent value communication and flexible contracting structures are essential to navigate differing reimbursement philosophies and budget constraints.

Competitive differentiation is increasingly anchored in scalable manufacturing, evidence generation, payer engagement, and partnership models that accelerate patient access and commercial sustainability

Competitive dynamics among companies operating in multiple myeloma therapeutics are increasingly defined by capabilities beyond core discovery and clinical development. Organizational agility in scaling complex biologic and cellular manufacturing, experience in navigating outcome-focused reimbursement negotiations, and the capacity to generate post-approval real-world evidence are now central determinants of commercial success. Companies focused on platform technologies such as CAR-T or bispecific antibodies are investing in the end-to-end value chain-ranging from vector production and cryogenic logistics to training of treatment centers-in order to reduce time-to-patient and improve consistency of outcomes.

At the same time, incumbents with established proteasome inhibitors, monoclonal antibodies, or immunomodulatory backbones are leveraging lifecycle management, combination studies, and administration route optimization to defend and extend their therapeutic roles. Strategic alliances, licensing deals, and manufacturing partnerships are common as firms seek to complement internal capabilities with external expertise in cell therapy manufacturing, digital health solutions for adherence, and specialty pharmacy networks for complex therapy coordination. Mergers and acquisitions trends reflect a blend of bolt-on acquisitions to secure manufacturing scale and larger strategic transactions aimed at building integrated platforms across discovery, development, and commercialization.

From a capabilities perspective, companies that succeed will combine deep clinical development expertise, scalable manufacturing operations, sophisticated health economics evidence generation, and nimble commercial models that can adapt to region-specific payer requirements. Leadership in patient support services, adherence management, and digital engagement tools further differentiates companies by smoothing the patient journey and demonstrating real-world value that supports payer negotiations and formulary positioning.

Actionable strategies for manufacturers and stakeholders to secure supply resilience, evidence-driven value, adaptive contracting, and patient-centric delivery models that accelerate uptake

Industry leaders should prioritize a set of pragmatic actions that align scientific potential with deliverable patient and commercial outcomes. First, invest proactively in manufacturing resilience and capacity diversification to mitigate supply chain and tariff risks, including qualification of alternate suppliers and strategic partnerships with contract manufacturers to support both bulk and specialized biologic production. Concurrently, embed real-world evidence generation into early development plans to support regulatory submissions, post-approval label expansions, and value-based contracting with payers, ensuring that data collection is interoperable and geographically relevant.

Second, design patient-centric delivery models that reduce administration burden and enhance adherence. Where clinically appropriate, pursue subcutaneous or oral formulations and integrate digital adherence tools and specialty pharmacy coordination to maintain continuity of care. Third, adopt flexible commercial contracting approaches that align pricing to measurable outcomes, exploring risk-sharing and subscription-style agreements to facilitate access while protecting long-term revenue streams. Fourth, tailor regional strategies to account for differences in infrastructure and reimbursement, prioritizing investments in local manufacturing or licensing in markets where tariffs or logistics materially affect cost-to-serve.

Finally, strengthen cross-functional capabilities by integrating regulatory, clinical, supply chain, and commercial teams early in development to anticipate adoption barriers and create executable launch plans. Leadership should also cultivate partnerships with centers of excellence and patient advocacy organizations to build trust and accelerate clinical uptake. These recommended actions collectively reduce execution risk, support sustainable access, and enable companies to convert scientific advances into durable patient and shareholder value.

A rigorous mixed-methods research approach combining secondary literature synthesis and targeted stakeholder interviews to validate clinical, operational, and commercial implications

The research underpinning these insights combined structured secondary intelligence review, targeted expert interviews, and thematic synthesis to create a balanced, practice-oriented perspective. Secondary analysis included interrogation of peer-reviewed clinical literature, public regulatory filings, clinical trial registries, and available policy statements to map recent approvals, label expansions, and changes in clinical practice. These sources informed the clinical and regulatory context without relying on proprietary market sizing or forecasting data, enabling a focus on therapeutic mechanisms, administration modalities, and evidence generation imperatives.

Primary research involved semi-structured interviews with a cross-section of stakeholders, including clinical opinion leaders, hospital pharmacy directors, specialty pharmacy operators, logistics and manufacturing experts, and payer advisors. Interviews were designed to surface operational constraints, adoption pain points, and the practical implications of tariff and supply chain shifts. Findings from primary and secondary research were triangulated to validate themes and to ensure that strategic recommendations reflect both macro-level trends and on-the-ground operational realities.

Analytical rigor was maintained through iterative synthesis and validation workshops with domain experts to challenge assumptions and refine implications. Limitations of the methodology include the evolving nature of advanced therapy manufacturing technologies and ongoing policy changes that may alter the regulatory and reimbursement landscape. Where appropriate, the research highlights areas of uncertainty and recommends ongoing evidence collection and scenario planning to adapt to emerging developments.

Synthesis of therapeutic innovation, operational execution, and policy dynamics that together determine the pace of patient access and commercial success in multiple myeloma

In conclusion, the therapeutic landscape for multiple myeloma is characterized by rapid innovation coupled with intricate operational and commercial requirements. Scientific advances are expanding the range of viable therapeutic strategies, but realization of patient benefit at scale depends on integrated execution across manufacturing, logistics, payer engagement, and clinical adoption. Tariff and supply chain dynamics have introduced new pressures that necessitate strategic sourcing, nearshoring consideration, and contractual flexibility to preserve access and margins.

Segmentation across drug class, mode of administration, distribution channels, and product type highlights where investments in evidence generation, manufacturing scale, and patient support will be most impactful. Regional heterogeneity requires tailored approaches to pricing, regulatory engagement, and infrastructure investments to match local delivery capabilities and payer expectations. Competitive success will go to organizations that marry scientific differentiation with operational excellence, robust health economics evidence, and adaptive commercial models that share risk and demonstrate long-term value.

Moving forward, stakeholders should continue to monitor regulatory developments, invest in data systems that capture real-world outcomes, and coordinate cross-functional planning early in development to optimize launch and access. By aligning innovation objectives with pragmatic execution, the therapeutic community can accelerate meaningful improvements in patient outcomes while navigating the complex commercial landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiple Myeloma Therapeutics Market, by Drug Class

  • 8.1. CAR-T Therapy
  • 8.2. Histone Deacetylase Inhibitor
  • 8.3. Immunomodulatory Drug
  • 8.4. Monoclonal Antibody
  • 8.5. Proteasome Inhibitor
    • 8.5.1. Bortezomib
    • 8.5.2. Carfilzomib
    • 8.5.3. Ixazomib

9. Multiple Myeloma Therapeutics Market, by Mode Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Multiple Myeloma Therapeutics Market, by Product Type

  • 10.1. Branded
  • 10.2. Generic

11. Multiple Myeloma Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Retail Pharmacy
  • 11.3. Specialty Pharmacy

12. Multiple Myeloma Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiple Myeloma Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiple Myeloma Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Multiple Myeloma Therapeutics Market

16. China Multiple Myeloma Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Adaptimmune Therapeutics plc
  • 17.7. Amgen Inc.
  • 17.8. Arcellx, Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Bluebird Bio, Inc.
  • 17.11. Bristol-Myers Squibb Company
  • 17.12. Cellectis S.A.
  • 17.13. Daiichi Sankyo Company, Limited
  • 17.14. Genmab A/S
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Glenmark Pharmaceuticals Ltd.
  • 17.18. Ichnos Sciences
  • 17.19. Ionis Pharmaceuticals, Inc.
  • 17.20. iTeos Therapeutics
  • 17.21. Johnson & Johnson Services, Inc.
  • 17.22. Karyopharm Therapeutics Inc.
  • 17.23. Merck & Co., Inc.
  • 17.24. Novartis AG
  • 17.25. Oncopeptides AB
  • 17.26. Poseida Therapeutics, Inc.
  • 17.27. Precision BioSciences, Inc.
  • 17.28. Regeneron Pharmaceuticals, Inc.
  • 17.29. Roche Holding AG
  • 17.30. Sanofi S.A.
  • 17.31. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 114. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 132. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 138. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)